Skip to main content


You are here

UMB Licensee Countervail Corporation Receives Additional $5.4 Million from BARDA for Continued Development of Medical Countermeasure to Nerve Agents

Sunday, November 10, 2013

Countervail Corporation announced on November 8 that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has exercised a contract option for an additional $5.4 million for the further development of galantamine hydrobromide, under the trade name AverTox(tm), as a medical countermeasure to the toxic effects of organophosphorus based nerve agents. BARDA exercised the option following an inter-agency In Process Review of the performance milestones completed by the company during the first phase of the contract.

Read the full press release